EFEK KLINIS APLIKASI SUBGINGIVAL RACIKAN GEL METRONIDASOL 25% DAN LARUTAN POVIDON-IODIN 10% SEBAGAI TERAPI PENUNJANG SKELING-PENGHALUSAN AKAR PADA PERIODONTITIS KRONIS

Trijani Suwandi

Abstract


Metronidazole gel 25% as an adjunct to scaling and root planing showed clinical effect better than scaling and root-planing alone. In Indonesia metronidazole gel is not popular, since probably it is expensive and not easy to obtain. So there is an idea to make metronidazole gel 25% mixture with relatively cheaper. The purpose of the study was to evaluate clinical effect of metronidazole gel 25%. Thirty Chronic Adult Periodontitis patients possessing at least 3 teeth ≥6mm pocket depth, ≥4mm attachment loss, and bleeding on probing were selected and grouped into metronidazole 25%, PVP-I 10%, and as controle respective. After SRP of all quadrant, 3 teeth were randomly selected as respectively metronidazole gel 25% and PVP-I 10% were applied on day 0 and day 7. BOP, PPD, and clinical attachment gain were recorded at baseline and 1 month post therapy. Bleeding on probing was analyzed using Kruskal-Wallis test, pocket depth and attachment gain were analyzed using Anova test. The result showed a significant difference in each group before and after the application. However, metronidazole group was the best compared to the other two groups.


Keywords


Metronidazole gel 25%; PVP-I 10%; scaling and root planing; chronic adult periodontitis

Full Text: PDF

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.
<a target="_new" rel="license" href="http://creativecommons.org/licenses/by/3.0/">
			<img alt="Creative Commons License" style="border-width:0" src="http://i.creativecommons.org/l/by/3.0/80x15.png"/>
		</a>
		<br/>
		This work is licensed under a <a rel="license" target="_new" href="http://creativecommons.org/licenses/by/3.0/">Creative Commons Attribution 3.0  License</a>.